Pharmarise Holdings Corporation
Stock Price Chart
2026/08/21 UpdatedPrice Trend
2026/08/21 UpdatedPrice & Trading Details
2026/08/21 UpdatedPRICE
TRADING
Shareholder Composition
Updated 2026/08/01Dividend History
Updated 2026/08/23| Year | Dividend | Change |
|---|---|---|
| 2026 | ¥14 | 0.0% |
| 2025 | ¥14 | -30.0% |
| 2024 | ¥20 | +42.9% |
| 2023 | ¥14 | 0.0% |
| 2022 | ¥14 | - |
Financial Performance
2026/08/23 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥51,608M | ¥52,030M | ¥54,466M | ¥63,508M |
| Gross Profit | ¥8,117M | ¥8,134M | ¥8,449M | ¥8,965M |
| Operating Income | ¥1,521M | ¥1,439M | ¥916M | ¥294M |
| Pretax Income | ¥1,387M | ¥1,104M | ¥209M | ¥186M |
| Net Income | ¥447M | ¥333M | -¥351M | -¥367M |
| EPS | ¥36.29 | ¥26.89 | -¥33.41 | -¥32.48 |
| Operating Margin | 2.95% | 2.77% | 1.68% | 0.46% |
| Balance Sheet | ||||
| Total Assets | ¥23,746M | ¥23,421M | ¥29,486M | ¥31,924M |
| Total Equity | ¥6,607M | ¥6,881M | ¥7,360M | ¥6,867M |
| Total Liabilities | ¥17,139M | ¥16,540M | ¥22,126M | ¥25,057M |
| Cash | ¥3,991M | ¥4,742M | ¥7,150M | ¥4,911M |
| Interest-bearing Debt | ¥9,912M | ¥9,138M | ¥12,749M | ¥14,279M |
| Equity Ratio | 27.82% | 29.38% | 24.96% | 21.51% |
| D/E Ratio | 1.50 | 1.33 | 1.73 | 2.08 |
| Cash Flow | ||||
| Operating CF | ¥713M | ¥2,520M | ¥2,714M | ¥1,311M |
| Investing CF | -¥292M | -¥703M | -¥3,120M | -¥4,462M |
| Financing CF | -¥1,034M | -¥1,072M | ¥2,771M | ¥939M |
| Free CF | ¥247M | ¥1,978M | ¥2,095M | ¥609M |
| Efficiency | ||||
| ROE | 6.77% | 4.84% | -4.77% | -5.34% |
| ROA | 1.88% | 1.42% | -1.19% | -1.15% |
Latest IR Information
-
Notice Regarding Receipt of Dividends from Consolidated Subsidiaries
Received 906 million yen in dividends from the consolidated subsidiary PharmaErase Co., Ltd. and two other subsidiaries. The dividends were decided by the subsidiary shareholders meeting on August 18, Reiwa 8 (2026), and the receipt date was August 19, Reiwa...
Read more -
Notice of Dividend Decision for FY 8 (Reiwa 8) ｜ Continuing Shareholder Returns
PharmaRise Holdings has decided on a final dividend of 14 yen per share for FY 8 (Reiwa 8), with the formal resolution scheduled at the shareholders meeting on August 28. The total dividend amount is 161 million yen, continuing its...
Read more -
Consolidated Financial Results Summary for the Fiscal Year Ending May 2024 [Japanese GAAP]
Read more -
Financial Results Summary for the Fiscal Year Ending May 2024 (Japanese GAAP, Consolidated)
Read more
Latest News (5 items)
Company Information
About
Pharmarise Holdings Corporation manages dispensing pharmacies in Japan. Its dispensing pharmacies provide patients with dispensing services based on prescriptions drawn up by medical institutions. The company also manages drug stores and convenience stores. In addition, it is involved in the storage and management of medical examination records of patients on behalf of medical institutions; and operation of medical malls. It also provides system integration services to pharmaceutical companies; medical IT solutions; and temporary help and employment placement services. The company was incorporated in 1984 and is headquartered in Tokyo, Japan.
